Synapse

← Journal of Market Access & Health Policy

Papers in Journal of Market Access & Health Policy

Page 5 · newest first

  1. Family caregiving in dementia and its impact on quality of life and economic burden in Japan-web based surveyJournal of Market Access & Health Policy · 2020
  2. Economic evaluation of biosimilars for reimbursement purposes – what, when, how?Journal of Market Access & Health Policy · 2020
  3. How to assess for the full economic value of vaccines? From past to present, drawing lessons for the futureJournal of Market Access & Health Policy · 2020
  4. Economic burden of spinal muscular atrophy: an analysis of claims dataJournal of Market Access & Health Policy · 2020
  5. Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et alJournal of Market Access & Health Policy · 2020
  6. Pricing of orphan drugs in oncology and rare diseasesJournal of Market Access & Health Policy · 2020
  7. Tendering and biosimilars: what role for value-added services?Journal of Market Access & Health Policy · 2019
  8. Management and clinical practice of multiple face and scalp actinic keratosis in FranceSHILAP Revista de lepidopterología · 2019
  9. Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemptionJournal of Market Access & Health Policy · 2019
  10. Results and validation of an index to measure health state of patients with depression in automated healthcare databasesJournal of Market Access & Health Policy · 2019
  11. Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databasesJournal of Market Access & Health Policy · 2019
  12. Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launchingJournal of Market Access & Health Policy · 2019
  13. Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimateJournal of Market Access & Health Policy · 2019
  14. Disparities of health service for the poor in the coastal area: does Universal health coverage reduce disparities?Journal of Market Access & Health Policy · 2019
  15. The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual frameworkJournal of Market Access & Health Policy · 2019
  16. Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settingsJournal of Market Access & Health Policy · 2019
  17. Measuring health-related quality of life in young children: how far have we come?Journal of Market Access & Health Policy · 2019
  18. Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugsJournal of Market Access & Health Policy · 2019
  19. Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling studyJournal of Market Access & Health Policy · 2019
  20. The impact of non-medical switching among ambulatory patients: an updated systematic literature reviewJournal of Market Access & Health Policy · 2019
  21. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patientsJournal of Market Access & Health Policy · 2019
  22. Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness resultsJournal of Market Access & Health Policy · 2019
  23. From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analysesJournal of Market Access & Health Policy · 2019
  24. President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients FirstJournal of Market Access & Health Policy · 2019
  25. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillationENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2019
  26. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overviewJournal of Market Access & Health Policy · 2019
  27. Characteristics of doctor-shoppers: a systematic literature reviewJournal of Market Access & Health Policy · 2019
  28. Health technology assessment (HTA) and economic evaluation: efficiency or fairness firstJournal of Market Access & Health Policy · 2018
  29. Non-profit drug research and development: the case study of GenethonJournal of Market Access & Health Policy · 2018
  30. Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UKJournal of Market Access & Health Policy · 2018
  31. Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapyJournal of Market Access & Health Policy · 2018
  32. Systematic review of pharmacoeconomic models for schizophreniaJournal of Market Access & Health Policy · 2018
  33. Assessment and diffusion of medical innovations in France: an overviewJournal of Market Access & Health Policy · 2018
  34. Budget impact of antimicrobial wound dressings in the treatment of venous leg ulcers in the German outpatient care sector: a budget impact analysisJournal of Market Access & Health Policy · 2018
  35. Patient-reported outcome claims in European and United States orphan drug approvalsJournal of Market Access & Health Policy · 2018
  36. Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016SHILAP Revista de lepidopterología · 2017
  37. Creating an index to measure health state of depressed patients in automated healthcare databases: the methodologyJournal of Market Access & Health Policy · 2017
  38. Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact testJournal of Market Access & Health Policy · 2017
  39. Key drivers for market penetration of biosimilars in EuropeJournal of Market Access & Health Policy · 2017
  40. A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutesJournal of Market Access & Health Policy · 2017
  41. Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in EuropeJournal of Market Access & Health Policy · 2017
  42. Ethical issues associated with medical tourism in AfricaJournal of Market Access & Health Policy · 2017
  43. Role of preliminary registry data in development of a clinical trial for an innovative device: a small but integral piece of a health policy initiativeJournal of Market Access & Health Policy · 2017
  44. Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*Journal of Market Access & Health Policy · 2017
  45. Policy implementation for methicillin-resistantStaphylococcus aureusin seven European countries: a comparative analysis from 1999 to 2015Journal of Market Access & Health Policy · 2017
  46. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European regionJournal of Market Access & Health Policy · 2017
  47. Gene therapies development: slow progress and promising prospectJournal of Market Access & Health Policy · 2017
  48. Supply-side and demand-side policies for biosimilars: an overview in 10 European member statesJournal of Market Access & Health Policy · 2017
  49. Towards a more comprehensive approach for a total economic assessment of vaccines?Journal of Market Access & Health Policy · 2017
  50. Healthcare resource use in schizophrenia, EuroSC findingsJournal of Market Access & Health Policy · 2017